Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Conventional therapy for acute myeloid leukemia is composed of remission induction with
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …

Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1
(PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not …

In the past few years, our improved knowledge of acute myeloid leukemia (AML)
pathogenesis has led to the accelerated discovery of new drugs and the development of …

The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors,
with limited progress made in the area of myeloid malignancies. The low mutational burden …

Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …

Background Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have
limited treatment options. In preclinical models of AML, inhibition of the PD‐1/PD‐L1 axis …

Single-cell and spatial multimodal technologies have propelled discoveries of the solid
tumor microenvironment (TME) molecular features and their correlation with clinical …